文献速递衰弱、肌少症与跌倒

EWGSOP2与FNIH肌少症定义在老年住院患者中的一致性及3年生存预测价值:GLISTEN研究

Comparing EWGSOP2 and FNIH Sarcopenia Definitions: Agreement and 3-Year Survival Prognostic Value in Older Hospitalized Adults: The GLISTEN Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2020-01-01

基于GLISTEN研究610例老年住院患者,比较EWGSOP2与FNIH肌少症定义的一致性及对3年死亡的预测价值。两种定义肌少症患病率分别为22.8%和23.9%,分类一致性低(Cohen kappa 0.29)。仅EWGSOP2定义在调整混杂因素后独立预测3年死亡(HR 1.84,95%CI 1.33-2.57)。

要点

  • EWGSOP2与FNIH定义肌少症患病率相近但分类一致性低(kappa 0.29)。
  • 仅EWGSOP2定义独立预测3年死亡(HR 1.84,95%CI 1.33-2.57)。
  • 同时满足两定义者生存期最短,但仅EWGSOP2阳性组死亡风险亦显著升高(HR 2.08)。

核心结论

  • EWGSOP2与FNIH肌少症定义的一致性差,EWGSOP2标准对老年住院患者3年死亡预测价值最高。

研究设计与样本

  • 对GLISTEN研究中610例老年住院患者进行队列分析,分别按EWGSOP2和FNIH定义分类肌少症,并构建四分组变量比较3年死亡预测价值。

主要发现

  • EWGSOP2和FNIH定义的肌少症患病率分别为22.8%和23.9%,分类一致性低(Cohen kappa 0.29)。
  • 两种定义下肌少症患者死亡率均高于非肌少症者(log-rank检验均p < .001)。
  • 同时满足两定义标准者生存期最短。
  • Cox模型调整混杂因素后,仅EWGSOP2定义预测3年死亡(HR 1.84;95%CI 1.33-2.57)。
  • 四分组分析中,与双阴性组相比,仅EWGSOP2阳性组(HR 2.08;95%CI 1.38-3.16)和双阳性组(HR 1.75;95%CI 1.11-2.79)死亡风险显著升高。

关键数值与推荐

  • EWGSOP2定义肌少症患病率22.8%,FNIH定义23.9%,两者一致性Cohen kappa为0.29。
  • EWGSOP2定义预测3年死亡HR 1.84(95%CI 1.33-2.57),仅EWGSOP2阳性组HR 2.08(95%CI 1.38-3.16),双阳性组HR 1.75(95%CI 1.11-2.79)。

临床怎么用

  • 对老年住院患者进行肌少症评估时,EWGSOP2标准可能较FNIH标准具有更优的3年死亡风险分层价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia is common among older hospitalized adults but estimates vary according to definitions used. Aims of this study were to investigate the agreement between the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project criteria and to compare the predictive value of both definitions for 3-year mortality. METHODS: Analysis was performed on 610 older hospitalized patients enrolled in the GLISTEN study. Participants were categorized as sarcopenic or not sarcopenic according to EWGSOP2 and FNIH definitions separately and in a four-group variable (neither criterion positive, only EWGSOP2, only FNIH, and both criteria). RESULTS: Sarcopenia prevalence was 22.8% and 23.9% using EWGSOP2 and FNIH criteria, respectively, with a low classification agreement (Cohen's kappa statistic: 0.29). Sarcopenic participants by each definitions had higher mortality rate when compared to those not sarcopenic (both log-rank test: p < .001). Participants who met both positive criteria had the shorter survival as compared with the other three groups. Cox models showed that, after adjustment for potential confounders, only EWGSOP2 definition predicted 3-year mortality (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.33-2.57). When the four-group variable was used, compared with the NO EWGSOP2/NO FNIH group, significant mortality risk was found for the EWGSOP2 (HR 2.08; 95% CI 1.38-3.16) and the combined EWGSOP2/FNIH group (HR 1.75; 95% CI 1.11-2.79). CONCLUSIONS: Agreement between EWGSOP2 and FNIH definitions is poor. Sarcopenia on hospital admission is associated with increased risk of 3-year mortality and EWGSOP2 criteria seem to have the highest predictive value.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Bianchi L, Maietti E, Abete P, et al. Comparing EWGSOP2 and FNIH Sarcopenia Definitions: Agreement and 3-Year Survival Prognostic Value in Older Hospitalized Adults: The GLISTEN Study. J Gerontol A Biol Sci Med Sci. 2020. PMID: 31628464. doi:10.1093/gerona/glz249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。